REGENXBIO to Participate in Stifel 2026 Healthcare Conference
REGENXBIO (Nasdaq: RGNX) will participate in the Stifel 2026 Healthcare Conference on November 11, 2026, in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO (Nasdaq: RGNX) will participate in the Stifel 2026 Healthcare Conference on November 11, 2026, in New York. Its fireside chat is scheduled for 9:20 a.m. ET. A live webcast will be accessible through the Investors section at www.regenxbio.com, with an archived replay available for approximately 30 days following the event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fireside Chat Details
Date and Time: Wednesday, November 11, 2026 at 9:20 a.m. ET
Location: New
A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcasts will be available for approximately 30 days following the event.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® and ITVISMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-stifel-2026-healthcare-conference-302927364.html
SOURCE REGENXBIO Inc.